May 14, 2020
December 31, 2019
MARKET OUTLOOKThe lucrative HR-positive, HER2-negative breast cancer market in Europe is fast-moving and competitive. CDK4/6 inhibitors Ibrance (Pfizer), Kisqali (Novartis) and Verzenios (Eli Lilly…
March 29, 2019
Market OutlookClinical pathways, which establish optimal treatment protocols for specific patient populations based on the best evidence, have become increasingly prevalent in the treatment of…
December 24, 2018
September 28, 2018
June 20, 2018
June 18, 2018
December 29, 2017
December 20, 2017
December 13, 2017